Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Sponsor: Whitehawk Therapeutics, Inc.
Summary
HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose escalation and dose expansion design without a control group.
Official title: A Phase 1 First-in-Human Study of PTK7-Directed Antibody Drug Conjugate HWK-007 in Participants With Advanced Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
226
Start Date
2025-12-19
Completion Date
2028-12
Last Updated
2026-03-27
Healthy Volunteers
No
Conditions
Interventions
HWK-007
HWK-007 is a PTK7- targeted ADC being developed for the treatment of solid tumors.
Locations (12)
University of Arkansas
Little Rock, Arkansas, United States
UCLA - Hematology/Oncology Clinical Research Unit
Los Angeles, California, United States
St. Francis Medical Center (OSF Healthcare)
Peoria, Illinois, United States
START - Midwest
Grand Rapids, Michigan, United States
Hackensack University Medical Center - John Theurer Cancer Center
Hackensack, New Jersey, United States
Roswell Park Comprehensive Care Center
Buffalo, New York, United States
University Hospital - Cleveland Medical Center
Cleveland, Ohio, United States
NEXT Oncology - Austin
Austin, Texas, United States
NEXT - Oncology - Houston
Houston, Texas, United States
START - San Antonio
San Antonio, Texas, United States
NEXT Oncology - Virginia Cancer Specialists
Fairfax, Virginia, United States
Fred Hutchinson Cancer Center
Seattle, Washington, United States